Framatome Healthcare and IBA are joining forces to develop an Astatine-211 Cyclotron Network, enabling industrial-scale production of this promising radioisotope for targeted alpha therapy.

With the pilot facility launching in France by 2027-2028, this marks a huge step in transforming cancer care.

At Tetrakit Technologies, we’re inspired by this progress and remain committed to advancing groundbreaking healthcare solutions.

Read the full article here: https://www.linkedin.com/feed/update/urn:li:activity:7294650280564940801